World’s best performing IPO in 2021 is a Korean bioscience firm
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard

Friday
August 19, 2022

Sign In
Subscribe
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
FRIDAY, AUGUST 19, 2022
World’s best performing IPO in 2021 is a Korean bioscience firm

Bloomberg Special

Filipe Pacheco, Bloomberg
07 December, 2021, 07:10 pm
Last modified: 07 December, 2021, 07:18 pm

Related News

  • Navana Pharma IPO subscription opens on 13 September
  • Korea, Unicef to support out-of-school adolescent girls in Bangladesh
  • Chartered Life allowed to raise Tk15cr through IPO
  • BTS rekindle debate about military service in South Korea
  • Raising capital through IPO drops 57% in FY22

World’s best performing IPO in 2021 is a Korean bioscience firm

SK Bioscience’s shares are up about 262% since they started trading in Seoul in the first quarter, the most among the 94 major offerings since January, according to data compiled by Bloomberg

Filipe Pacheco, Bloomberg
07 December, 2021, 07:10 pm
Last modified: 07 December, 2021, 07:18 pm
SK Bioscience’s IPO at the Korea Exchange in March 2021.  Photographer: SeongJoon Cho/Bloomberg
SK Bioscience’s IPO at the Korea Exchange in March 2021. Photographer: SeongJoon Cho/Bloomberg

South Korean biopharmaceutical firm SK Bioscience Co is the top gainer among initial public offerings that raised more than $1 billion this year, leading a ranking dominated by listings from that country.

SK Bioscience's shares are up about 262% since they started trading in Seoul in the first quarter, the most among the 94 major offerings since January, according to data compiled by Bloomberg. The IPO raised $1.3 billion for the firm, which is a local Covid-19 vaccine-production partner with AstraZeneca Plc.

World's 10 Best-Performing IPOs in 2021

The company was the first among five Korean firms that raised more than $1 billion each through new-share offers this year, with several tech-related names also surging in their trading debuts. Most of those deals were buoyed by strong participation by retail investors. Ballooning valuations made regulators step up scrutiny as the year progressed. 

SK Bioscience also outperformed two major listings in Shanghai, China Three Gorges Renewables Group and Zhuzhou CRRC Times Electric Co., which are each up more than 140%. Several other Korean names appear within the 10 top performers globally for the year, including Kakao Pay Corp., KakaoBank Corp. and SK IE Technology Co., giving the country more representation in the ranking than any market.

Shares of SK Bioscience surged to a record high in August after local media reported that the company would start shipping 1.1 million doses at that time. The company also got a boost from the inclusion in indexes tracked by MSCI Inc. in the same month.

But part of those stellar gains have already faded, with the stock retreating about 16% since the start of December. It is among an array of Asian health-care shares that dropped on Tuesday, following a slump in U.S. biotech companies, as investors reacted to reports suggesting cases of the omicron variant have been relatively mild.

The health-care firm has eight buy recommendations and no sell or hold calls among analysts tracked by Bloomberg.


Disclaimer: This article first appeared on Bloomberg. It has been edited and published by a special syndication arrangement.

Analysis / Top News / Global Economy

Korea / IPO / SK Bioscience Co

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Stories beneath the trade data
    Stories beneath the trade data
  • Photo: Collected
    India also will be ashamed of FM Momen’s statement: Quader
  • Logo of BNP
    BNP slams Momen for 'asking India to keep PM Hasina's govt in power'

MOST VIEWED

  • Photographer: NurPhoto/NurPhoto
    India aims to copy China, but not in lending-by-app craze
  • Russia's war in Ukraine is how the soviet union finally ends
    Russia's war in Ukraine is how the soviet union finally ends
  • As average temperatures rise and heat waves become more frequent and intense, it’s become clear that infrastructure and in particular roads are vulnerable to accelerating global warming.Photographer: Robert Michael/Picture Alliance/Getty Images
    The world’s roads aren’t ready for a hotter climate
  • Photo: Bloomberg
    A $379 billion hole emerges in developing nations’ war chests
  • A diesel fuel tank at a supplier in the US.Photographer: Luke Sharrett/Bloomberg
    A storm brews in heating oil
  • Cap: Liquefied natural gas prices in Asia are now near $50 per million British thermal units. Photo: Reuters
    World embraces dirtier fuels as gas hits exorbitant heights

Related News

  • Navana Pharma IPO subscription opens on 13 September
  • Korea, Unicef to support out-of-school adolescent girls in Bangladesh
  • Chartered Life allowed to raise Tk15cr through IPO
  • BTS rekindle debate about military service in South Korea
  • Raising capital through IPO drops 57% in FY22

Features

Illustration: TBS

China-Bangladesh currency clearance agreement can increase trade by 'an unimaginable scale': Li Jiming, Ambassador of China

12h | Interviews
Postcrossing (which connects people through its website) is a system built for postcard enthusiasts, where anyone can sign up and create an account for free. Photo: Noor A Alam

Postcrossers: Reviving a lost art with strangers and postcards

11h | Panorama
We will be facing massive, recurring challenges in the coming years no matter what. Photo: Reuters

Holes in the recession story

1d | Panorama
Illustration: Bloomberg

What nonmonogamy can teach moonlighters and job jugglers

1d | Pursuit

More Videos from TBS

Amazing folding smartphone

Amazing folding smartphone

3h | Videos
How Russia gets advantage for geographical location?

How Russia gets advantage for geographical location?

4h | Videos
Is textbooks enough for students?

Is textbooks enough for students?

5h | Videos
134-year-old traditional sandwich of New York

134-year-old traditional sandwich of New York

10h | Videos

Most Read

1
From left Afzal Karim, Murshedul Kabir and Mohammad Jahangir
Banking

Sonali, Agrani and Rupali banks get new MDs

2
Russia now offers Bangladesh finished oil
Energy

Russia now offers Bangladesh finished oil

3
Photo: TBS
Bangladesh

5 crushed to death as BRT girder falls on car in Uttara

4
Photo: Collected
Economy

Bangladesh is not in a crisis situation: IMF

5
Dollar price drops by Tk8 in kerb market
Economy

Dollar price drops by Tk8 in kerb market

6
Eight more banks make unusual gains from forex dealings
Banking

Eight more banks make unusual gains from forex dealings

EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2022
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net